Research Advance of CXCR4 Inhibitors in the Treatment of Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2021.04.055
- Author:
Jing-Ping LIANG
1
;
Wei LI
2
Author Information
1. Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
2. Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China,E-mail: liwei160@yahoo.com.
- Publication Type:Review
- MeSH:
Antineoplastic Agents/therapeutic use*;
Apoptosis;
Bone Marrow;
Chemokine CXCL12/pharmacology*;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Receptors, CXCR4;
Signal Transduction
- From:
Journal of Experimental Hematology
2021;29(4):1355-1359
- CountryChina
- Language:Chinese
-
Abstract:
CXCL12/CXCR4 axis composed of chemokine CXCL12 and its specific ligand CXCR4 can regulate and control the adhesion of leukemia cells to protective bone marrow niche, promote cell survival, and resist apoptosis induced by signal transduction inhibitors and chemotherapeutic drugs. Therefore, CXCL12 /CXCR4 axis has become a new target for the treatment of acute myeloid leukemia. At present, CXCR4 inhibitors that have been developed are in different clinical trials, showing good anti-leukemia effect. In this review, the research advance of CXCR4 inhibitors in the treatment of acute myeloid leukemia is summarized briefly.
